What does CHO Pharma, Inc. do?

CHO Pharma, Inc. (6586.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is 6586.TWO's market cap?

CHO Pharma, Inc. (6586.TWO) has a market capitalization of approximately $23.86 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.

Does 6586.TWO pay a dividend?

No — CHO Pharma, Inc. (6586.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is 6586.TWO profitable?

CHO Pharma, Inc. (6586.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

6586.TWO

CHO Pharma, Inc.

TWO·Biotechnology · Healthcare

NT$111.50NT$0.50−0.45%

Market capNT$23.86B·Market closed·Aug 26 6:59 AM UTC

Price Chart

NT$111.50−NT$0.50 (−0.45%)today

+110.78%CAGR +16.08%

Select date range

FromTo

Sep 28, 2017Aug 26, 2021 → Aug 26, 2026· 5.0 yrsAug 26, 2026

Key Metrics

6586.TWO does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings Date—

Last Report Date—

Reported vs Estimate—

Earnings Surprise—

FinancialsFinancials Tab

RevenueNT$1.71M

Net Income−NT$268.04M

Net Margin−15,720.9%

Operating Cash Flow−NT$241.25M

Capital ExpendituresNT$8.53M

Free Cash Flow−NT$249.78M

Return on Equity−11.3%

Return on Invested Capital−4.7%

Net CashNT$1.95B

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for 6586.TWO and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how 6586.TWO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 6586.TWO and 80,000+ other tickers.

About CHO Pharma, Inc.

CHO Pharma, Inc., a biotechnology firm headquartered in Taipei City, Taiwan, specializes in the research and development of innovative therapeutic solutions. Central to its operations is an advanced glycoengineering platform. This proprietary technology facilitates the creation of several key therapeutic modalities, including SAR-based glycoengineered "biobetters," site-specific antibody-drug conjugates (ADCs), and novel antibodies and vaccines designed to target unique carbohydrate antigens. The company also offers CHOptimax, an innovative in vitro enzymatic single-step process. This…

CEO: Chung-Yi Wu
Sector: Healthcare
Industry: Biotechnology
Exchange: TWO
Employees: 35
Website: www.chopharma.com

Peers

TaiGen Biopharmaceuticals Holdings Limited

Cap

NT$6.5B

Latest News

News Tab

No recent news available.

Frequently Asked Questions About 6586.TWO

What does CHO Pharma, Inc. do?: CHO Pharma, Inc. (6586.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is 6586.TWO's market cap?: CHO Pharma, Inc. (6586.TWO) has a market capitalization of approximately $23.86 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.
Does 6586.TWO pay a dividend?: No — CHO Pharma, Inc. (6586.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is 6586.TWO profitable?: CHO Pharma, Inc. (6586.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.